BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 26565788)

  • 1. Evaluating Serum Markers for Hormone Receptor-Negative Breast Cancer.
    Schummer M; Thorpe J; Giraldez MD; Bergan L; Tewari M; Urban N
    PLoS One; 2015; 10(11):e0142911. PubMed ID: 26565788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer.
    Anderson KS; Wong J; Vitonis A; Crum CP; Sluss PM; Labaer J; Cramer D
    Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):859-68. PubMed ID: 20200435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of paraneoplastic antigens reveals TRIM21 autoantibodies as biomarker for early detection of ovarian cancer in combination with autoantibodies to NY-ESO-1 and TP53.
    Hurley LC; Levin NK; Chatterjee M; Coles J; Muszkat S; Howarth Z; Dyson G; Tainsky MA
    Cancer Biomark; 2020; 27(3):407-421. PubMed ID: 32083570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.
    Wang YJ; Huang XY; Mo M; Li JW; Jia XQ; Shao ZM; Shen ZZ; Wu J; Liu GY
    Asian Pac J Cancer Prev; 2015; 16(11):4603-8. PubMed ID: 26107211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma Autoantibodies Associated with Basal-like Breast Cancers.
    Wang J; Figueroa JD; Wallstrom G; Barker K; Park JG; Demirkan G; Lissowska J; Anderson KS; Qiu J; LaBaer J
    Cancer Epidemiol Biomarkers Prev; 2015 Sep; 24(9):1332-40. PubMed ID: 26070530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A panel of autoantibodies as potential early diagnostic serum biomarkers in patients with breast cancer.
    Liu Y; Liao Y; Xiang L; Jiang K; Li S; Huangfu M; Sun S
    Int J Clin Oncol; 2017 Apr; 22(2):291-296. PubMed ID: 27778118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multiparametric serum marker panel as a complementary test to mammography for the diagnosis of node-negative early-stage breast cancer and DCIS in young women.
    Lacombe J; Mangé A; Bougnoux AC; Prassas I; Solassol J
    Cancer Epidemiol Biomarkers Prev; 2014 Sep; 23(9):1834-42. PubMed ID: 24957886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in prediagnostic breast cancer sera.
    Lu H; Ladd J; Feng Z; Wu M; Goodell V; Pitteri SJ; Li CI; Prentice R; Hanash SM; Disis ML
    Cancer Prev Res (Phila); 2012 Aug; 5(8):1036-43. PubMed ID: 22715141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer.
    Yang WL; Gentry-Maharaj A; Simmons A; Ryan A; Fourkala EO; Lu Z; Baggerly KA; Zhao Y; Lu KH; Bowtell D; Jacobs I; Skates SJ; He WW; Menon U; Bast RC;
    Clin Cancer Res; 2017 Oct; 23(19):5912-5922. PubMed ID: 28637689
    [No Abstract]   [Full Text] [Related]  

  • 10. Identification of Specific miRNA Signature in Paired Sera and Tissue Samples of Indian Women with Triple Negative Breast Cancer.
    Thakur S; Grover RK; Gupta S; Yadav AK; Das BC
    PLoS One; 2016; 11(7):e0158946. PubMed ID: 27404381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating microRNAs as specific biomarkers for breast cancer detection.
    Ng EK; Li R; Shin VY; Jin HC; Leung CP; Ma ES; Pang R; Chua D; Chu KM; Law WL; Law SY; Poon RT; Kwong A
    PLoS One; 2013; 8(1):e53141. PubMed ID: 23301032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples.
    Kazarian A; Blyuss O; Metodieva G; Gentry-Maharaj A; Ryan A; Kiseleva EM; Prytomanova OM; Jacobs IJ; Widschwendter M; Menon U; Timms JF
    Br J Cancer; 2017 Feb; 116(4):501-508. PubMed ID: 28081538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selenium-Binding Protein 1 (SBP1) autoantibodies in ovarian disorders and ovarian cancer.
    Yu-Rice Y; Edassery SL; Urban N; Hellstrom I; Hellstrom KE; Deng Y; Li Y; Luborsky JL
    Reproduction; 2017 Mar; 153(3):277-284. PubMed ID: 27965399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship between serum p53 autoantibodies and characteristics of human breast cancer.
    Mudenda B; Green JA; Green B; Jenkins JR; Robertson L; Tarunina M; Leinster SJ
    Br J Cancer; 1994 Jun; 69(6):1115-9. PubMed ID: 8198980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression.
    Eichelser C; Flesch-Janys D; Chang-Claude J; Pantel K; Schwarzenbach H
    Clin Chem; 2013 Oct; 59(10):1489-96. PubMed ID: 23748853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of blood-based miRNAs as diagnostic and prognostic nucleic acid markers in breast cancer: Comparative to conventional tumor markers.
    Swellam M; Ramadan A; El-Hussieny EA; Bakr NM; Hassan NM; Sobeih ME; EzzElArab LR
    J Cell Biochem; 2019 Aug; 120(8):12321-12330. PubMed ID: 30825229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Shotgun proteomics coupled to nanoparticle-based biomarker enrichment reveals a novel panel of extracellular matrix proteins as candidate serum protein biomarkers for early-stage breast cancer detection.
    Fredolini C; Pathak KV; Paris L; Chapple KM; Tsantilas KA; Rosenow M; Tegeler TJ; Garcia-Mansfield K; Tamburro D; Zhou W; Russo P; Massarut S; Facchiano F; Belluco C; De Maria R; Garaci E; Liotta L; Petricoin EF; Pirrotte P
    Breast Cancer Res; 2020 Dec; 22(1):135. PubMed ID: 33267867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating microRNAs miR-331 and miR-195 differentiate local luminal a from metastatic breast cancer.
    McAnena P; Tanriverdi K; Curran C; Gilligan K; Freedman JE; Brown JAL; Kerin MJ
    BMC Cancer; 2019 May; 19(1):436. PubMed ID: 31077182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-throughput and multi-phases identification of autoantibodies in diagnosing early-stage breast cancer and subtypes.
    Luo R; Zheng C; Song W; Tan Q; Shi Y; Han X
    Cancer Sci; 2022 Feb; 113(2):770-783. PubMed ID: 34843149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P53 autoantibodies in sera from Danish ovarian cancer patients and their correlation with clinical data and prognosis.
    Høgdall EV; Høgdall CK; Blaakaer J; Heegaard NH; Glud E; Christensen L; Bock JE; Nørgaard-Pedersen B; Wiik A; Kjaer SK
    APMIS; 2002 Aug; 110(7-8):545-53. PubMed ID: 12390412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.